Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Vitamin D and Reduced CHI3L1 Level

Doses used in studies

IU/week: 50,000 (median 50,000, IQR 50,000–50,000) — 1 study

Time to effect

Median: 8 weeks · IQR 8 weeks–8 weeks · Range 8 weeks–8 weeks — Reported in 1 of 1 study

1 of 1 paper

Vitamin D3 Supplementation Modulates Inflammatory Protein CHI3L1/YKL-40 and Oxidative Stress Status in Multiple Sclerosis.
- 2025-11-23
- Clinical Trial · n = 35
- Neuropsychopharmacology reports 45(4)
- - Sevda Asadpour
  - Mehrdokht Mazdeh
  - Jamshid Karimi
  - Iraj Khodadadi
  - Gholamreza Shafiee
- PubMed: 41277171
- DOI: 10.1002/npr2.70076
11 Insights on
- Reduced CHI3L1 Level
- High evidence
- Clinical
CHI3L1 concentration decreased by 21.7% (33.28±8.9 to 26.05±9.1 ng/mL; p<0.001).
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
50 000 IU/week